TDOC

Prezzo Teladoc Health Inc

Closed
TDOC
$7,22
+$0,25(+3,58%)

*Data last updated: 2026-05-10 17:16 (UTC+8)

As of 2026-05-10 17:16, Teladoc Health Inc (TDOC) is priced at $7,22, with a total market cap of $1,30B, a P/E ratio of -6,15, and a dividend yield of 0,00%. Today, the stock price fluctuated between $6,79 and $7,39. The current price is 6,33% above the day's low and 2,30% below the day's high, with a trading volume of 5,94M. Over the past 52 weeks, TDOC has traded between $5,05 to $7,39, and the current price is -2,30% away from the 52-week high.

TDOC Key Stats

Yesterday's Close$6,96
Market Cap$1,30B
Volume5,94M
P/E Ratio-6,15
Dividend Yield (TTM)0,00%
Diluted EPS (TTM)0,96
Net Income (FY)-$200,32M
Revenue (FY)$2,52B
Earnings Date2026-07-29
EPS Estimate0,24
Revenue Estimate$615,29M
Shares Outstanding188,00M
Beta (1Y)2.081

About TDOC

Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.
SectorHealthcare
IndustryMedical - Healthcare Information Services
CEOCharles Divita
HeadquartersPurchase,NY,US
Employees (FY)5,60K
Average Revenue (1Y)$451,78K
Net Income per Employee-$35,77K

Teladoc Health Inc (TDOC) FAQ

What's the stock price of Teladoc Health Inc (TDOC) today?

x
Teladoc Health Inc (TDOC) is currently trading at $7,22, with a 24h change of +3,58%. The 52-week trading range is $5,05–$7,39.

What are the 52-week high and low prices for Teladoc Health Inc (TDOC)?

x

What is the price-to-earnings (P/E) ratio of Teladoc Health Inc (TDOC)? What does it indicate?

x

What is the market cap of Teladoc Health Inc (TDOC)?

x

What is the most recent quarterly earnings per share (EPS) for Teladoc Health Inc (TDOC)?

x

Should you buy or sell Teladoc Health Inc (TDOC) now?

x

What factors can affect the stock price of Teladoc Health Inc (TDOC)?

x

How to buy Teladoc Health Inc (TDOC) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts su Teladoc Health Inc (TDOC)

ZKProofster

ZKProofster

2025-12-26 02:08
Teladoc Health, Inc. [TDOC](/market-activity/stocks/tdoc) is making waves in the virtual care space with a strategic partnership that could reshape how remote patient examinations are conducted. The company is bringing TytoCare's breakthrough Home Smart Clinic—an FDA-approved diagnostic device—into its Primary360 and 24/7 Care networks starting in 2026. This integration marks a pivotal moment for the telehealth industry, as clinical-grade remote examination capabilities move from luxury feature to mainstream offering. ## What Makes This Partnership Game-Changing TytoCare's technology represents a notable leap in diagnostic capability. The device enables clinicians to remotely assess critical health indicators: lung function, cardiac rhythms, throat conditions, ear pathology, dermatological issues, and body temperature—all with the precision that mirrors in-person clinical examination. But the real standout is its recently FDA-cleared AI-powered Lung Sounds Suite, which won TIME's 2025 Best Invention recognition for good reason. Here's why this matters: respiratory conditions drive over 40% of diagnoses on the TytoCare platform. The AI-enhanced system can distinguish between three major categories of abnormal lung sounds, a capability that has historically required specialist-level assessment. This is significant advancement in democratizing diagnostic accuracy at scale. TytoCare's dataset of over 7 million recorded examinations strengthens the reliability of these AI models, creating a powerful feedback loop between real-world clinical data and algorithmic improvement. ## The Market Opportunity and Patient Impact For employers and health plans backing these platforms, the implications are substantial. Earlier intervention becomes possible, preventable emergency room visits drop, and chronic disease management—whether asthma, hypertension, or COPD—improves through continuous monitoring. The cost structure of virtual care suddenly becomes more defensible when diagnostic confidence is backed by AI-validated clinical examination. From TDOC's perspective, this move enhances its market positioning during a critical period. Virtual care providers face mounting pressure to justify long-term value propositions, and integrating this level of diagnostic sophistication is a credible answer to skeptics. The rollout strategy reveals caution: TDOC is starting with select customer segments, carefully evaluating adoption patterns, utilization rates, and reimbursement alignment before broader expansion. If execution succeeds, this integration could become a scalable competitive advantage. ## Stock Performance and Investment Outlook TDOC shares have declined 23% year-to-date, underperforming the healthcare sector's 4.9% growth. The stock currently carries a Zacks Rank #3 (Hold) rating. For investors seeking stronger positions in the healthcare space, Zacks currently highlights three stocks with #1 (Strong Buy) rankings: **BrightSpring Health Services, Inc.** [BTSG](/market-activity/stocks/btsg) shows current-year earnings consensus of $1.12 per share with three upward estimate revisions in the past month. The company has beaten earnings expectations for four consecutive quarters with an average surprise of 45.1%. Revenue guidance sits at $12.7 billion, representing 12.8% year-over-year expansion. **Universal Health Services, Inc.** [UHS](/market-activity/stocks/uhs) carries a consensus current-year earnings estimate of $21.67 per share, backed by six upward revisions over 30 days. It has delivered earnings surprises in four straight quarters averaging 15.2%. The company projects current-year revenues of $17.4 billion, implying 9.7% annual growth. **Veracyte, Inc.** [VCYT](/market-activity/stocks/vcyt) maintains a current-year earnings consensus of $1.42 per share with one upward revision in the past 60 days. The company achieved earnings surprises in four consecutive quarters with an average of 45.1%. Revenue estimates are pegged at $508.6 million, suggesting 14.1% year-over-year growth trajectory. ## The Bigger Picture The TDOC-TytoCare partnership reflects a broader industry shift: clinical diagnostics are migrating toward patient homes and convenience. What once seemed like a premium service—comprehensive at-home examination with AI-backed clinical intelligence—may soon become the baseline expectation in modern healthcare delivery. The success of this integration will ultimately depend on execution. Reimbursement frameworks must align, adoption must accelerate beyond early adopter segments, and the clinical outcomes must validate the technology's promise. If TDOC navigates these challenges effectively, this partnership could redefine the competitive landscape for telehealth providers and investor confidence in virtual care sustainability.
0
0
0
0